BioSpace News Archive

Biotech Bay

Tempest Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - Jan 05, 2024

Tempest Therapeutics, Inc. announced that on January 3, 2024 the Compensation Committee of the Company’s Board of Directors granted one employee a nonqualified stock option to purchase 4,500 shares of its common stock under the Company’s 2023 Inducement Plan.

January 5, 2024
·
1 min read
Biotech Bay

Senti Bio Announces Strategic Steps to Prioritize Investment in Lead Clinical Program

Senti Biosciences, Inc. announced plans to streamline its business operations, including reducing its workforce by approximately 37 percent, to enable increased focus on SENTI-202, a first-in-class Logic Gated investigational cell therapy for the treatment of acute myeloid leukemia.

January 5, 2024
·
8 min read
Genetown

Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) - Jan 05, 2024

Syndax Pharmaceuticals announced that on January 1, 2024 the Company granted inducement awards to purchase up to 8,600 shares of common stock to one new employee under the Company’s 2023 Inducement Plan.

January 5, 2024
·
1 min read
Addex to Present at Biotech Showcase™ 2024

Addex Therapeutics announced that Tim Dyer, Chief Executive Officer, will present at Biotech Showcase being held in San Francisco, January 8-10, 2024.

January 5, 2024
·
3 min read
Genetown

Kymera Therapeutics Announces Pricing of $275 Million Public Offering

Kymera Therapeutics, Inc. (NASDAQ: KYMR) today announced the pricing of its underwritten public offering of $275 million of shares of its common stock and, in lieu of common stock to certain investors, pre-funded warrants to purchase shares of its common stock.

January 5, 2024
·
6 min read
Delta-Fly Pharma Inc.: Update on the R&D status of DFP-10917 and DFP-14927, a novel PEG Drug Conjugate, in the patients with R/R AML

A Phase I/II study of DFP-10917 in the combination with Venetoclax (VTX) in patients with R/R AML in the U.S. is in preparation.

January 5, 2024
·
1 min read
Drug Development

Theravance Biopharma Announces Results from the Phase 4 YUPELRI® PIFR-2 Study in Patients with Severe to Very Severe Chronic Obstructive Pulmonary Disease (COPD)

Theravance Biopharma, Inc. (NASDAQ: TBPH) today announced results from the Phase 4 PIFR-2 study of YUPELRI® (revefenacin) inhalation solution, the only once-daily, nebulized long-acting muscarinic antagonist (LAMA) approved in the U.S. for maintenance treatment of COPD.

January 5, 2024
·
10 min read
Kexing Biopharm Introduces Eribulin Mesylate Injection, Expanding Its Overseas Product Portfolio

On the morning of January 3, Kexing Biopharm signed an international commercialization cooperation agreement on Eribulin Mesylate Injection, securing exclusive commercialization licensing and supply of the product from Xiling Lab Co., Ltd. in 36 countries.

January 5, 2024
·
2 min read
Genetown

Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Jan 05, 2024

Apellis Pharmaceuticals, Inc. announced that the company approved the grant of equity awards to 2 new employees with a grant date of January 2, 2024, as equity inducement awards outside of the company’s 2017 Stock Incentive Plan and material to the employees’ acceptance of employment with the company.

January 5, 2024
·
2 min read
Business

Barinthus Bio Provides a Financial Update and Announces Anticipated 2024 Corporate Milestones

Barinthus Biotherapeutics plc (NASDAQ: BRNS), formerly Vaccitech plc, today provided a preliminary financial update and announced its 2024 corporate objectives.

January 5, 2024
·
7 min read